Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Journal of Controlled Release : Official Journal of the Controlled Release Society|September 22, 1998
Targeting of human and mouse T-lymphocytes by monoclonal antibody-HPMA copolymer-doxorubicin conjugates directed against different T-cell surface antigensM Jelínková, J Strohalm, D Plocová, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|April 12, 2002
Differences in the intracellular fate of free and polymer-bound doxorubicinOndrej Hovorka, M St'astný, T Etrych, et al.
Selective Cancer Therapeutics|January 1, 1991
Synthetic polymers conjugated to monoclonal antibodies: vehicles for tumour-targeted drug deliveryL W Seymour, P A Flanagan, A al-Shamkhani, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|September 24, 2004
HPMA copolymers containing doxorubicin bound by a proteolytically or hydrolytically cleavable bond: comparison of biological properties in vitroM Kovár, L Kovár, V Subr, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|January 21, 2000
Polymeric drugs based on conjugates of synthetic and natural macromolecules. II. Anti-cancer activity of antibody or (Fab')(2)-targeted conjugates and combined therapy with immunomodulatorsB Ríhová, M Jelínková, J Strohalm, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|March 8, 2008
Doxorubicin release is not a prerequisite for the in vitro cytotoxicity of HPMA-based pharmaceuticals: in vitro effect of extra drug-free GlyPheLeuGly sequencesB Ríhová, J Strohalm, O Hovorka, et al.
Scandinavian Journal of Immunology|June 15, 2005
Induction of systemic antitumour resistance with targeted polymersB Rihova, J Strohalm, M Kovar, et al.
Pageof 3